(Q28256557)

Toward a new understanding of attention-deficit hyperactivity disorder pathophysiology: an important role for prefrontal cortex dysfunction

21 January 2018

1 reference

Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

Reduction of prefrontal cortex glucose metabolism common to three types of depression

21 January 2018

1 reference

Is the forced swimming test a suitable model for revealing antidepressant activity?

21 January 2018

1 reference

Measuring uptake rates in intact tissue

21 January 2018

1 reference

Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder

21 January 2018

1 reference

Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex

21 January 2018

1 reference

Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex: evidence that dopamine is taken up in vivo by noradrenergic terminals

21 January 2018

1 reference

Unfaithful neurotransmitter transporters: focus on serotonin uptake and implications for antidepressant efficacy

21 January 2018

1 reference

The role of dopamine in the pathophysiology of depression

21 January 2018

1 reference

Effect of an uptake inhibitor on serotonin metabolism in rat brain: Studies with 3-(p-trifluoromethylphenoxy)-n-methyl-3-phenylpropylamine (Lilly 110140)

21 January 2018

1 reference

From the Golgi-Cajal mapping to the transmitter-based characterization of the neuronal networks leading to two modes of brain communication: wiring and volume transmission

21 January 2018

1 reference

Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users

21 January 2018

1 reference

Ghrelin receptor antagonism attenuates cocaine- and amphetamine-induced locomotor stimulation, accumbal dopamine release, and conditioned place preference

21 January 2018

1 reference

Stressful life events and previous episodes in the etiology of major depression in women: an evaluation of the "kindling" hypothesis

21 January 2018

1 reference

The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R)

21 January 2018

1 reference

Ex vivo assessment of binding site occupancy of monoamine reuptake inhibitors: methodology and biological significance

21 January 2018

1 reference

Influence of fluoxetine on the ability of bupropion to modulate extracellular dopamine and norepinephrine concentrations in three mesocorticolimbic areas of rats

21 January 2018

1 reference

Antidepressant-like pharmacological profile of a novel triple reuptake inhibitor, (1S,2S)-3-(methylamino)-2-(naphthalen-2-yl)-1-phenylpropan-1-ol (PRC200-SS)

21 January 2018

1 reference

Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response.

21 January 2018

1 reference

Diminished neural processing of aversive and rewarding stimuli during selective serotonin reuptake inhibitor treatment

21 January 2018

1 reference

1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors

21 January 2018

1 reference

An integrative theory of prefrontal cortex function

21 January 2018

1 reference

Atomoxetine blocks motor hyperactivity in neonatal 6-hydroxydopamine-lesioned rats: implications for treatment of attention-deficit hyperactivity disorder

21 January 2018

1 reference

Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study

21 January 2018

1 reference

The role of the brain reward system in depression

21 January 2018

1 reference

Monoamine releasers with varying selectivity for dopamine/norepinephrine versus serotonin release as candidate "agonist" medications for cocaine dependence: studies in assays of cocaine discrimination and cocaine self-administration in rhesus monkeys

21 January 2018

1 reference

Resolution of sleepiness and fatigue in major depressive disorder: A comparison of bupropion and the selective serotonin reuptake inhibitors

21 January 2018

1 reference

Modelling late-life depression

21 January 2018

1 reference

Anhedonia in schizophrenia and major depression: state or trait?

21 January 2018

1 reference

Pharmacological profile of the "triple" monoamine neurotransmitter uptake inhibitor, DOV 102,677.

21 January 2018

1 reference

Depression: a new animal model sensitive to antidepressant treatments

21 January 2018

1 reference

Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression

21 January 2018

1 reference

Alpha1-adrenoceptors modulate citalopram-induced serotonin release.

21 January 2018

1 reference

Subjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant users

21 January 2018

1 reference

Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis

21 January 2018

1 reference

Can recovery from depression be achieved?

21 January 2018

1 reference

Regional differences in extracellular dopamine and serotonin assessed by in vivo microdialysis in mice lacking dopamine and/or serotonin transporters.

21 January 2018

1 reference

Triple reuptake inhibitors ("broad spectrum" antidepressants).

21 January 2018

1 reference

Antidepressant-like actions of DOV 21,947: a "triple" reuptake inhibitor

21 January 2018

1 reference

Multiple recurrences of major depressive disorder.

21 January 2018

1 reference

Effect of the attention deficit/hyperactivity disorder drug atomoxetine on extracellular concentrations of norepinephrine and dopamine in several brain regions of the rat.

21 January 2018

1 reference

The triple uptake inhibitor (1R,5S)-(+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0] hexane hydrochloride (DOV 21947) reduces body weight and plasma triglycerides in rodent models of diet-induced obesity

21 January 2018

1 reference

Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

Catecholaminergic strategies for the treatment of major depression

21 January 2018

1 reference

Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice

21 January 2018

1 reference

Medication augmentation after the failure of SSRIs for depression.

21 January 2018

1 reference

An antihyperkinetic action by the serotonin 1A-receptor agonist osemozotan co-administered with psychostimulants or the non-stimulant atomoxetine in mice

21 January 2018

1 reference

Uptake and release of norepinephrine by serotonergic terminals in norepinephrine transporter knock-out mice: implications for the action of selective serotonin reuptake inhibitors.

21 January 2018

1 reference

Variables That Affect the Clinical Use and Abuse of Methylphenidate in the Treatment of ADHD

21 January 2018

1 reference

Brain reward circuitry: insights from unsensed incentives

21 January 2018

1 reference

Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: twenty years since its first publication

21 January 2018

1 reference

The spontaneously hypertensive rat as an animal model of attention-deficit hyperactivity disorder: effects of methylphenidate on exploratory behavior.

21 January 2018

1 reference

Use of bupropion in combination with serotonin reuptake inhibitors

21 January 2018

1 reference

Serotonin transporters are located on the axons beyond the synaptic junctions: anatomical and functional evidence.

21 January 2018

1 reference